DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, ...

The Emerging Paradigm of Skin Wellness. Contemporary skincare now extends beyond superficial treatments, emphasizing an ...

Report with market evolution powered by AI - The global wound care market size is estimated to grow by USD 6.95 billion from ...

Minimally invasive techniques require only small incisions, reducing the likelihood of complications and promoting a quicker ...

Humacyte ( (HUMA) ) has provided an announcement. Humacyte, Inc. has announced a $15 million registered direct offering, selling common stock ...

Organogenesis (NASDAQ:ORGO – Get Free Report) will release its earnings data after the market closes on Tuesday, November ...

DURHAM, N.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at ...

Humacyte, Inc. recently announced the presentation of results from the V007 phase 3 clinical trial of the company’s acel ...

both those that occur naturally and in bioengineered materials. A particularly important aspect of this field is imaging and sensing cells and tissue. This includes injecting fluorescent markers ...

The Kobe University bioengineer Hasunuma Tomohisa says, "To obtain a high-yield and low-cost supply, it is desirable to produce it in bioengineered microorganisms which can be grown in fermenters." ...

Researchers have identified a potential treatment for Sandhoff and Tay-Sachs diseases -- two rare, often fatal lysosomal storage disorders that cause progressive damage to nerve cells in the brain and ...